Novartis Investigative Site

Pointe-Claire, Quebec H9R 4S3

0 studies enrolling now · 6 studies all time

What they study most

Anklyosing Spondylitis, Arthritis, Psoriatic, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease (COPD), Psoriatic Arthritis, Spondylitis, Ankylosing, Type 2 Diabetes Mellitus

Studies at this site

• Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis — Completed
• 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis — Completed
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis — Completed
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis — Completed
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation. — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early